Your quote(s) are like a fish bone stuck in my throat for sure. I wish you had knot closed by letting them of the hook. Pun intended.

Quote:

---

If we are to believe Dr.NP that the DSMC was ONLY looking at safety and not efficacy, then there would not have been a need for any endpoint threshold to have been achieved (neither 14 nor 28). In other words, the entire universe of treatment arm subjects could have been reviewed for AE or SAE.

It seems we're not getting the full story here.

---

Quote:

---

There may be a reasonable explanation for why a DSMC review that was described by the company as being initiated for the sole purpose of potentially terminating the trial due to overwhelming efficacy -- was later described as only looking at the safety of leronlimab.

---